Q1 2026 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2026-05-15 · accession 0001420506-26-001151
$759.2M
Reported value
54
Positions
2026-03-31
Period end
The Brief · Opaleye Management Inc. · Q1 2026
AI · grounded in 13F
Opaleye Management Inc. closed its position in ALKS, reducing its exposure by $13.71M. The fund also exited positions in GOSS and KPTI, totaling $15.28M in combined divestments. On the buy side, the fund increased its holdings in MGTX by 443.25% and URGN by 432.74%. Overall, the fund added 28 new positions and reduced 23 others, ending the period with $759.22M in total assets under management.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW INC | $99.9M | 13.2% | 2,832,230 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $88.8M | 11.7% | 2,545,000 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $70.6M | 9.30% | 2,860,000 | Common | SOLE |
| M8694L137 | SLGL | SOL-GEL TECHNOLOGIES LTD | $39.6M | 5.22% | 500,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $35.3M | 4.65% | 123,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $32.8M | 4.32% | 390,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $26.9M | 3.55% | 421,000 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $25.7M | 3.39% | 1,430,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $24.1M | 3.18% | 1,312,615 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $22.8M | 3.00% | 700,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $19.5M | 2.57% | 4,675,000 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $19.2M | 2.53% | 6,300,000 | Common | SOLE |
| G59665102 | MGTX | MEIRAGTX HLDGS PLC | $18.4M | 2.42% | 2,123,259 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $17.8M | 2.34% | 535,000 | Common | SOLE |
| 80303D305 | SNWV | SANUWAVE HEALTH INC | $17.0M | 2.23% | 981,267 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $15.8M | 2.07% | 500,000 | Common | SOLE |
| 02074J501 | ACOG | ALPHA COGNITION INC | $14.1M | 1.85% | 2,561,950 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $12.9M | 1.70% | 2,331,761 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $12.1M | 1.60% | 550,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $11.1M | 1.46% | 6,785,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $10.5M | 1.39% | 100,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $9.7M | 1.28% | 100,000 | Common | SOLE |
| 98419J206 | XOMA | XOMA ROYALTY CORPORATION | $9.4M | 1.24% | 300,000 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $8.1M | 1.06% | 1,256,228 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $7.8M | 1.02% | 260,000 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $6.5M | 0.86% | 935,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $6.4M | 0.85% | 94,800 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $6.0M | 0.79% | 427,608 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $5.1M | 0.67% | 600,000 | Common | SOLE |
| 04546C304 | ASRT | ASSERTIO HOLDINGS INC | $5.1M | 0.67% | 265,707 | Common | SOLE |
| 28106W103 | EDIT | EDITAS MEDICINE INC | $4.8M | 0.63% | 1,926,997 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $4.7M | 0.63% | 190,671 | Common | SOLE |
| 48115J109 | DERM | JOURNEY MED CORP | $4.5M | 0.59% | 960,000 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $4.4M | 0.58% | 1,150,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $4.1M | 0.54% | 345,100 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $3.8M | 0.50% | 123,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $3.7M | 0.49% | 1,380,000 | Common | SOLE |
| 09075X207 | BDSX | BIODESIX INC | $3.5M | 0.45% | 238,047 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $3.4M | 0.45% | 955,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $3.3M | 0.44% | 1,412,656 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $3.1M | 0.41% | 245,000 | Common | SOLE |
| 34960Q307 | FBIO | FORTRESS BIOTECH INC | $2.9M | 0.38% | 1,042,000 | Common | SOLE |
| 67577R102 | IRD | OPUS GENETICS INC | $2.3M | 0.30% | 1,120,000 | Common | SOLE |
| 766559702 | RIGL | RIGEL PHARMACEUTICALS INC | $1.9M | 0.25% | 70,000 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $1.7M | 0.23% | 322,600 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $1.6M | 0.21% | 79,097 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $1.6M | 0.21% | 125,000 | Common | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $1.5M | 0.20% | 141,181 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $1.0M | 0.14% | 112,291 | Common | SOLE |
| 46489V902 | CATX | PERSPECTIVE THERAPEUTICS INC | $834,000 | 0.11% | 200,000 | Common | SOLE |
| 74365A309 | PLX | PROTALIX BIOTHERAPEUTICS INC | $737,800 | 0.10% | 340,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $476,874 | 0.06% | 53,282 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $357,718 | 0.05% | 14,506 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $21,211 | 0.00% | 18,444 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.